Ying Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ying Wu has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Barbara S. Slusher
Johns Hopkins Drug Discovery, Johns Hopkins University School of Medicine, Baltimore, MD, USA
13 shared publications Chabely Rodriguez
13 shared publications- Cory Brayton
Johns Hopkins University
13 shared publications - Jaishri O. Blakeley
Johns Hopkins University School of Medicine, Baltimore, MD
13 shared publications - Jenny Lam
Center for Organ and Cell Transplantation, Scripps Health, La Jolla, CA
13 shared publications - Jesse Alt
Department of Neurology, Johns Hopkins School of Medicine, Baltimore, Maryland. 10
13 shared publications
Latest Publications
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Supplemental Figure 4: Weight changes in non-tumored NPcis mice over one month of daily JHU395 dosing.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Supplemental Figure 4: Weight changes in non-tumored NPcis mice over one month of daily JHU395 dosing.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Supplemental Table 1: List of significantly affected metabolites identified in volcano plot following JHU395 versus vehicle treatment of flank MPNST
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Supplemental Table 1: List of significantly affected metabolites identified in volcano plot following JHU395 versus vehicle treatment of flank MPNST
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 1 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Supplemental Figure 1: JHU395 and DON treatment of sNF02.2 MPNST cells, evaluation of PARP cleavage following JHU395 treatment in sNF96.2 cells, and effects of DON and JHU395 on oxygen consumption rates in sNF96.2 MPNST cells.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 1 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Supplemental Figure 1: JHU395 and DON treatment of sNF02.2 MPNST cells, evaluation of PARP cleavage following JHU395 treatment in sNF96.2 cells, and effects of DON and JHU395 on oxygen consumption rates in sNF96.2 MPNST cells.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 5 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Supplemental Figure 5: 13C5-glutamine in vivo flux analysis in vehicle vs JHU395 treated tumors
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 5 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Supplemental Figure 5: 13C5-glutamine in vivo flux analysis in vehicle vs JHU395 treated tumors
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 3 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Supplemental Figure 3: Ex vivo JHU395 vs vehicle treated tumor histological analyses and plasma glutamine from non-tumored mice
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 3 from The Novel Glutamine Antagonist Prodrug JHU395 Has Antitumor Activity in Malignant Peripheral Nerve Sheath Tumor
Supplemental Figure 3: Ex vivo JHU395 vs vehicle treated tumor histological analyses and plasma glutamine from non-tumored mice